Recent Updates
Recently added Catalysts
TECH Positive Sentiment Score: 75/100

Bio-Techne to Present at Investor Conferences Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 45th Annual Health Care...

Key Takeaway: Bio-Techne Corporation (NASDAQ: TECH) announced its participation in several upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The presentations are scheduled for March 4, 2025, March 11, 2025, and March 12, 2025. A live webcast of the presentations will be available on the company's Investor Relations website. Bio-Techne continues to bolster its presence in the life sciences sector, supporting research and clinical diagnostics with a vast array of products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bio-Techne is actively engaging with investors through multiple conferences.
  • The company has a significant portfolio with a broad range of products.
  • Bio-Techne reported strong financial performance with $1.2 billion in net sales.

Full Press Release Details

MINNEAPOLIS , Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that it will present at the following investor conferences:
TD Cowen 45 th Annual Health Care Conference March 4, 2025 2:30 PM EST
Leerink Partners Global Healthcare Conference March 11, 2025 11:20 AM EDT
Barclays 27 th Annual Global Healthcare Conference March 12, 2025 10:00 AM EDT
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .
About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH ) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook , LinkedIn , Twitter or YouTube .
Contact: David Clair , Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416
SOURCE Bio-Techne Corporation

21 %

Frequently Asked Questions

When is Bio-Techne presenting at the TD Cowen Conference?

Bio-Techne will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 2:30 PM EST.

Where can I access Bio-Techne's live presentations?

Live webcasts of Bio-Techne's presentations can be found on their Investor Relations website.

What type of company is Bio-Techne Corporation?

Bio-Techne Corporation is a global life sciences company providing innovative research tools and reagents.

How much did Bio-Techne generate in net sales in fiscal 2024?

Bio-Techne generated approximately $1.2 billion in net sales during fiscal 2024.

Last updated: Feb 27, 2025